<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40493525</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-1612</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Pharmaceutical statistics</Title><ISOAbbreviation>Pharm Stat</ISOAbbreviation></Journal><ArticleTitle>Applying Bias Correction Methods to Build Hybrid Controls Using Real-World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis.</ArticleTitle><Pagination><StartPage>e70020</StartPage><MedlinePgn>e70020</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pst.70020</ELocationID><Abstract><AbstractText>Studies incorporating randomized controlled trial (RCT) controls with real-world (RW) patients face concerns of selection bias and unmeasured confounding. To evaluate two methods (Match, Test-then-Pool [MTP] and Matching and Bias Adjustment [MBA]) to construct a hybrid control arm using concurrent RCT control patients and trial-eligible RW patients from the CorEvitas Rheumatoid Arthritis (RA) Registry to replicate the treatment effect obtained from the original RCT. The measures considered estimate the effect of baricitinib on the proportion achieving 20% improvement in American College of Rheumatology response (ACR20) and change in disease activity (Clinical Disease Activity Index, CDAI) for patients with moderately to severely active rheumatoid arthritis. Patients included RCT treated (n&#x2009;=&#x2009;102), a 50% random sample of the RCT control (n&#x2009;=&#x2009;49), and trial-eligible RW (n&#x2009;=&#x2009;359). MTP used optimal propensity score (PS) matching to replace half of the RCT control group with a comparable RW control group (n&#x2009;=&#x2009;49) and tested for differences between RCT and RW control outcomes before combining into the hybrid control arm for analysis. MBA leveraged 3 sets of optimal PS matches to identify a RW control group and adjusted for residual differences in outcomes between RCT and RW controls during analysis when creating the hybrid control arm. Optimal matching produced a matched RW cohort with satisfactory balance on the majority of key covariates compared to RCT participants. Using MTP, the odds ratio (OR) for ACR20 from covariate adjusted modeling was 4.71 (95% confidence interval [CI] 2.51, 9.15). Using MBA, ACR20 treatment effect from bias and covariate adjusted modeling was 4.76 (2.10, 10.81). For reference, the OR for the treatment difference of ACR20 for the trial-eligible population was 3.81 (2.13, 6.95) and was 4.74 (2.32, 10.00) for the RCT population with 50% sample of controls. With MTP with covariate adjustment, the treatment effect of mean CDAI change was -8.96 (-12.58, -5.35). For MBA with bias and covariate adjustment, the treatment effect of mean CDAI change was -9.85 (-15.16, -5.02). In the original RCT, the mean CDAI change was -8.88 (-12.58, -5.18) and for the RCT population with 50% sample of controls, the mean CDAI change was -10.10 (-14.46, -5.74). With both hybrid control methods using the combination of well-matched RWD and RCT control patients, we replicated the Phase IIb trial results. Trial Registration: Data were used from Eli Lilly and Company's clinical trial (NCT01185353) and the CorEvitas Rheumatoid Arthritis Registry (NCT01402661), both registered at clinicaltrials.gov.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Litman</LastName><ForeName>Heather J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-3511-4078</Identifier><AffiliationInfo><Affiliation>CorEvitas, LLC, Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Kristin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pugach</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CorEvitas, LLC, Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Mingyang</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7131-562X</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakin</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CorEvitas, LLC, Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Zhanglin Lin</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrold</LastName><ForeName>Leslie R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>CorEvitas, LLC, Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01402661</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Eli Lilly and Company</Agency><Country/></Grant><Grant><Agency>CorEvitas LLC</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharm Stat</MedlineTA><NlmUniqueID>101201192</NlmUniqueID><ISSNLinking>1539-1604</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="Y">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="Y">Azetidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="Y">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="Y">Clinical Trials, Phase II as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">external control arm</Keyword><Keyword MajorTopicYN="N">hybrid control arm</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword><Keyword MajorTopicYN="N">real&#x2010;world data</Keyword><Keyword MajorTopicYN="N">registry data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40493525</ArticleId><ArticleId IdType="doi">10.1002/pst.70020</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. Burcu, N. A. Dreyer, J. M. Franklin, et&#xa0;al., &#x201c;Real&#x2010;World Evidence to Support Regulatory Decision&#x2010;Making for Medicines: Considerations for External Control Arms,&#x201d; Pharmacoepidemiology and Drug Safety 29, no. 10 (2020): 1228&#x2013;1235.</Citation></Reference><Reference><Citation>H. Schmidli, D. A. Haring, M. Thomas, et&#xa0;al., &#x201c;Beyond Randomized Clinical Trials: Use of External Controls,&#x201d; Clinical Pharmacology and Therapeutics 107, no. 4 (2020): 806&#x2013;816.</Citation></Reference><Reference><Citation>United States Department of Health and Human Services Food and Drug Administration, &#x201c;Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products: Guidance for Industry,&#x201d; 2023, https://www.fda.gov/media/164960/download.</Citation></Reference><Reference><Citation>L. H. Curtis, O. Sola&#x2010;Morales, J. Heidt, et&#xa0;al., &#x201c;Regulatory and HTA Considerations for Development of Real&#x2010;World Data Derived External Controls,&#x201d; Clinical Pharmacology and Therapeutics 114, no. 2 (2023): 303&#x2013;315.</Citation></Reference><Reference><Citation>L. V. Hampson and R. Izem, &#x201c;Innovative Hybrid Designs and Analytical Approaches Leveraging Real&#x2010;World Data and Clinical Trial Data,&#x201d; in Real&#x2010;World Evidence in Medical Product Development (Springer International Publishing, 2023), 211&#x2013;232.</Citation></Reference><Reference><Citation>M. Shan, D. Faries, A. Dang, X. Zhang, Z. Cui, and K. M. Sheffield, &#x201c;A Simulation&#x2010;Based Evaluation of Statistical Methods for Hybrid Real&#x2010;World Control Arms in Clinical Trials,&#x201d; Statistics in Biosciences 14, no. 2 (2022): 259&#x2013;284.</Citation></Reference><Reference><Citation>O. Sola&#x2010;Morales, L. H. Curtis, J. Heidt, et&#xa0;al., &#x201c;Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions,&#x201d; Clinical Pharmacology and Therapeutics 114, no. 2 (2023): 325&#x2013;355.</Citation></Reference><Reference><Citation>S. Ventz, S. Khozin, B. Louv, et&#xa0;al., &#x201c;The Design and Evaluation of Hybrid Controlled Trials That Leverage External Data and Randomization,&#x201d; Nature Communications 13, no. 1 (2022): 5783.</Citation></Reference><Reference><Citation>R. R. Velummailum, C. McKibbon, D. R. Brenner, E. A. Stringer, L. Ekstrom, and L. Dron, &#x201c;Data Challenges for Externally Controlled Trials: Viewpoint,&#x201d; Journal of Medical Internet Research 25 (2023): e43484.</Citation></Reference><Reference><Citation>H. U. Burger, C. Gerlinger, C. Harbron, et&#xa0;al., &#x201c;The Use of External Controls: To What Extent Can It Currently Be Recommended?,&#x201d; Pharmaceutical Statistics 20, no. 6 (2021): 1002&#x2013;1016.</Citation></Reference><Reference><Citation>K. Thorlund, L. Dron, J. J. H. Park, and E. J. Mills, &#x201c;Synthetic and External Controls in Clinical Trials &#x2013; A Primer for Researchers,&#x201d; Clinical Epidemiology 12 (2020): 457&#x2013;467.</Citation></Reference><Reference><Citation>L. Dron, S. Golchi, G. Hsu, and K. Thorlund, &#x201c;Minimizing Control Group Allocation in Randomized Trials Using Dynamic Borrowing of External Control Data&#x2014;An Application to Second Line Therapy for Non&#x2010;Small Cell Lung Cancer,&#x201d; Contemporary Clinical Trials Communications 16 (2019): 100446.</Citation></Reference><Reference><Citation>M. Ghadessi, R. Tang, J. Zhou, et&#xa0;al., &#x201c;A Roadmap to Using Historical Controls in Clinical Trials&#x2014;By Drug Information Association Adaptive Design Scientific Working Group (DIA&#x2010;ADSWG),&#x201d; Orphanet Journal of Rare Diseases 15, no. 1 (2020): 69.</Citation></Reference><Reference><Citation>J. Hainmueller, &#x201c;Entropy Balancing for Causal Effects: A Multivariate Reweighting Method to Produce Balanced Samples in Observational Studies,&#x201d; Political Analysis 20, no. 1 (2012): 25&#x2013;46.</Citation></Reference><Reference><Citation>United States Department of Health and Human Services Food and Drug Administration, &#x201c;Data Standards for Drug and Biological Product Submissions Containing Real&#x2010;World Data: Guidance for Industry,&#x201d; 2023, https://www.fda.gov/media/153341/download.</Citation></Reference><Reference><Citation>United States Department of Health and Human Services Food and Drug Administration, &#x201c;Real&#x2010;World Data: Assessing Registries to Support Regulatory Decision&#x2010;Making for Drug and Biological Products: Guidance for Industry,&#x201d; 2023, https://www.fda.gov/media/154449/download.</Citation></Reference><Reference><Citation>C. Gao, S. Yang, M. Shan, et&#xa0;al., &#x201c;Integrating Randomized Placebo&#x2010;Controlled Trial Data With External Controls: A Semiparametric Approach With Selective Borrowing,&#x201d; arXiv Preprint arXiv: 2306. 166642, 2023.</Citation></Reference><Reference><Citation>E. C. Keystone, P. C. Taylor, E. Drescher, et&#xa0;al., &#x201c;Safety and Efficacy of Baricitinib at 24&#x2009;Weeks in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate,&#x201d; Annals of the Rheumatic Diseases 74, no. 2 (2015): 333&#x2013;340.</Citation></Reference><Reference><Citation>J. M. Kremer, &#x201c;The CORRONA Database,&#x201d; Clinical and Experimental Rheumatology 23, no. 5 Suppl 39 (2005): S172&#x2013;S177.</Citation></Reference><Reference><Citation>K. Viele, S. Berry, B. Neuenschwander, et&#xa0;al., &#x201c;Use of Historical Control Data for Assessing Treatment Effects in Clinical Trials,&#x201d; Pharmaceutical Statistics 13, no. 1 (2014): 41&#x2013;54.</Citation></Reference><Reference><Citation>E. A. Stuart and D. B. Rubin, &#x201c;Matching With Multiple Control Groups With Adjustment for Group Differences,&#x201d; Journal of Educational and Behavioral Statistics 33, no. 3 (2008): 279&#x2013;306.</Citation></Reference><Reference><Citation>J. S. Smolen, F. C. Breedveld, G. Eberl, et&#xa0;al., &#x201c;Validity and Reliability of the Twenty&#x2010;Eight&#x2010;Joint Count for the Assessment of Rheumatoid Arthritis Activity,&#x201d; Arthritis &amp; Rheumatism 38, no. 1 (1995): 38&#x2013;43.</Citation></Reference><Reference><Citation>J. D. Greenberg, M. Kishimoto, V. Strand, et&#xa0;al., &#x201c;Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort,&#x201d; American Journal of Medicine 121, no. 6 (2008): 532&#x2013;538.</Citation></Reference><Reference><Citation>P. C. Austin, &#x201c;Balance Diagnostics for Comparing the Distribution of Baseline Covariates Between Treatment Groups in Propensity&#x2010;Score Matched Samples,&#x201d; Statistics in Medicine 28, no. 25 (2009): 3083&#x2013;3107.</Citation></Reference><Reference><Citation>X. S. Gu and P. R. Rosenbaum, &#x201c;Comparison of Multivariate Matching Methods: Structures, Distances, and Algorithms,&#x201d; Journal of Computational and Graphical Statistics 2, no. 4 (1993): 405&#x2013;420.</Citation></Reference><Reference><Citation>D. B. Rubin, Multiple Imputation for Nonresponse in Surveys (John Wiley &amp; Sons Inc., 1987).</Citation></Reference><Reference><Citation>L. Wu and S. Yang, &#x201c;Integrative R&#x2010;Learner of Heterogeneous Treatment Effects Combining Experimental and Observational Studies,&#x201d; in Proceedings of the 1st Conference on Causal Learning and Reasoning, PMLR, 140, 1&#x2013;S5, 2022.</Citation></Reference><Reference><Citation>Y. Cheng, L. Wu, and S. Yang, &#x201c;Enhancing Treatment Effect Estimation: A Model Robust Approach Integrating Randomized Experiments and External Controls Using the Double Penalty Integration Estimator,&#x201d; 2023 UAI (39th Conference on Uncertainty in Artificial Intelligence).</Citation></Reference><Reference><Citation>C. Fu, H. Pang, S. Zhou, and J. Zhu, &#x201c;Covariate Handling Approaches in Combination With Dynamic Borrowing for Hybrid Control Studies,&#x201d; Pharmaceutical Statistics 22, no. 4 (2023): 619&#x2013;632.</Citation></Reference><Reference><Citation>S. Sengupta, I. Ntambwe, K. Tan, et&#xa0;al., &#x201c;Emulating Randomized Controlled Trials With Hybrid Control Arms in Oncology: A Case Study,&#x201d; Clinical Pharmacology and Therapeutics 113, no. 4 (2023): 867&#x2013;877.</Citation></Reference><Reference><Citation>W. K. Tan, B. D. Segal, M. D. Curtis, et&#xa0;al., &#x201c;Augmenting Control Arms With Real&#x2010;World Data for Cancer Trials: Hybrid Control Arm Methods and Considerations,&#x201d; Contemporary Clinical Trials Communications 30 (2022): 101000.</Citation></Reference><Reference><Citation>P. R. Rosenbaum and D. B. Rubin, &#x201c;The Central Role of the Propensity Score in Observational Studies for Causal Effects,&#x201d; Biometrika 70, no. 1 (1983): 41&#x2013;55.</Citation></Reference><Reference><Citation>H. Akaike, &#x201c;Information Theory and an Extension of the Maximum Likelihood Principle,&#x201d; in Proceedings of the Second International Symposium on Information Theory, ed. B. N. Petrov and F. Csaki (Akademiai Kiado, 1973), 267&#x2013;281.</Citation></Reference><Reference><Citation>X. S. Gu and P. R. Rosenbaum, &#x201c;Comparison of Multivariate Matching Methods: Structures, Distances, and Algorithms,&#x201d; Journal of Computational and Graphical Statistics 2, no. 4 (1993): 405&#x2013;420.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>